Article Details
Retrieved on: 2021-03-08 03:42:22
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Its anti-PCSK9 monoclonal antibody was the first in China to be approved for clinical trials by the NMPA. In early 2020, Junshi Biosciences joined forces ...
Article found on: www.prnewswire.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here